Inflow Improve for Deep Vein ThrombOsis with Ultrasound AcceLerated ThrombOlysis and Venoplasty

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-29

Study Completion Date

2027-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the IDOLO study is to investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).

At San Raffaele Hospital (Vascular Surgery Department) will be enrolled 50 patients with lower extremity deep vein thrombosis (who have failed conservative treatment) objectively diagnosed with imaging ≥ 6 months; prior persistent deep vein Thrombosis (DVT) at enrollment evaluation and moderate-severe post-thrombotic syndrome at time of procedure

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Simplification of the Diagnosis of Deep Vein Thrombosis

NCT01412242

Deep Venous Thrombosis

COMPLETED PHASE3

Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis

NCT01482273

Venous Thrombosis Postthrombotic Syndrome

COMPLETED NA

Natural History of Isolated Deep Vein Thrombosis of the Calf

NCT00816920

Isolated Distal DVT Proximal DVT Pulmonary Embolism

COMPLETED

Ultrasound Assessment of Isolated Distal Deep Vein Thrombosis

NCT06596941

Iddvt Pulmonary Embolism (PE)

ACTIVE_NOT_RECRUITING

The ERASMUS Study: Limited vs Extended US for DVT Diagnosis

NCT00353093

Deep Vein Thrombosis of the Lower Extremities

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post-Thrombotic Syndrome of Both Legs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DVT patients

ultrasound accelerated thrombolysis and venoplasty

Intervention Type OTHER

IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ultrasound accelerated thrombolysis and venoplasty

IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient admitted in Vascular Surgery Unit, San Raffaele Hospital, Milan
* Patients able to sign specific informed consent for the study.
* Proximal deep vein Thrombosis (iliac vein, common femoral vein, deep femoral vein, and femoral vein) that was objectively diagnosed with duplex imaging and/or venography ≥ 6 months prior to study screening.
* Persistent chronic deep vein Thrombosis causing restrictive flow, as confirmed by imaging, within 60 days prior to the study procedure.
* Failed a minimum of 3 consecutive months of conservative treatment (therapeutic anticoagulation and compression stockings).
* Villalta score ≥8 for the affected limb within 30 days prior to the study procedure

Exclusion Criteria

* Treated with mechanical thrombectomy within 2 weeks of the study thrombolysis procedure.
* Treated with thrombolysis drugs within 48 hours of the study thrombolytic procedure.
* Life expectancy less than (\<) 1 year.
* Body Mass Index (BMI) greater than (\>) 40 kilograms/square meter (kg/m\^2) or per Investigator's discretion participant is able tolerate the procedure and be compliant with post-procedure increased physical activity.
* No flow in popliteal vein on duplex imaging
* Thrombus extending ≥ 3 centimeters (cm) into the inferior vena cava (IVC). If central venous occlusion, consider computed tomography (CT) or magnetic resonance venography (MRV). For participants with bilateral DVT, it is recommended that central imaging be performed prior to treatment to evaluate the status of the IVC.
* Active bleeding, recent (\<3 months) gastrointestinal (GI) bleeding, active peptic ulcer, severe liver dysfunction, and bleeding diathesis.
* Recent (\<3 months) internal eye surgery or hemorrhagic retinopathy; recent (\<10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation (CPR), obstetrical delivery, or other invasive procedure.
* History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, or aneurysm.
* Active cancer (metastatic, progressive, or treated within the last 6 months). Participants with non-melanoma primary skin cancers are eligible to participate in the study.
* Hemoglobin \<9.0 milligrams/deciliter (mg/dL) within 24 hours prior to the procedure
* International normalized ratio (INR) ≥1.5 nanograms/deciliter (ng/dL) within 24 hours prior to the procedure.
* Platelet count \<100,000 cells/cubic millimeter (cells/mm\^3) or \>700,000 cells/mm\^3 within 24 hours prior to the procedure.
* Creatinine outside the normal range for the treating institution and considered clinically significant by the Investigator.
* Uncontrolled hypertension, defined as systolic \>175 millimeters of mercury (mmHg) and a diastolic \>110 mmHg.
* Use of clopidogrel, ticlopidine, or other thienopyridine antiplatelet drug within 7 days of the study procedure.
* In the judgment of the clinician, the participant is at high risk for catastrophic bleeding.
* Impossibility or refusal to give informed consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No